Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | DRD4 | P21917 | 4/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | DRD3 | P35462 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.49 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11665859 | 0.80 | ALDH1A1 (0.56) | TSHRKMT2ALMNAMAPTMEN1 | |
| SCHEMBL15486035 | 0.79 | L3MBTL1 (0.57) | L3MBTL1KDM4ETSHRCYP2D6HIF1A | |
| SCHEMBL14064868 | 0.79 | LMNA (0.67) | L3MBTL1KDM4ETSHRCYP2D6HIF1A | |
| SCHEMBL4577971 | 0.77 | L3MBTL1 (0.97) | L3MBTL1KDM4ETSHRCYP2D6HIF1A | |
| SCHEMBL3970369 | 0.77 | L3MBTL1 (0.97) | L3MBTL1KDM4ETSHRCYP2D6HIF1A | |
| SCHEMBL11240406 | 0.77 | L3MBTL1 (0.97) | L3MBTL1KDM4ETSHRCYP2D6HIF1A | |
| SCHEMBL267463 | 0.75 | LMNA (0.68) | L3MBTL1KDM4ETSHRCYP2D6HIF1A | |
| SCHEMBL15105717 | 0.75 | ALDH1A1 (0.42) | L3MBTL1KDM4ETSHRCYP2D6HIF1A | |
| SCHEMBL9770539 | 0.74 | ALOX12 (0.54) | TSHRKMT2ALMNAMAPTMEN1 | |
| SCHEMBL25010831 | 0.74 | KDM4E (1.00) | L3MBTL1KDM4ETSHRCYP2D6HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105102428-B | Novel DPP-IV inhibitors | DNJ制药有限公司 | 2018-11-16 | — | — | CN | disclosed |
| EP-2945930-B1 | NOVEL DDP-IV INHIBITORS | DNJ PHARMA INC (US) | 2018-10-10 | — | — | EP | disclosed |
| EP-2945930-A1 | NOVEL DDP-IV INHIBITORS | DNJ Pharma Inc. (US) | 2015-11-25 | — | — | EP | disclosed |
| US-9115082-B2 | Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension | YANG CATHERINE (US) | 2015-08-25 | — | — | US | disclosed |
| WO-2014113750-A1 | NOVEL DDP-IV INHIBITORS | DNJ PHARMA, INC. (US) | 2014-07-24 | — | — | WO | disclosed |
| US-20130184322-A1 | NOVEL DIPEPTIDYL-PEPTIDASE-IV INHIBITORS | LI WEIXING (US) | 2013-07-18 | — | — | US | disclosed |
| US-4450173-A | BRIEF ACTING B-ADRENERGIC BLOCKING AGENTS; BIOLOGICAL INJECTIONS; ANTIARRYHYTHMIA AGENTS | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1984-05-22 | — | — | US | disclosed |
| EP-0065963-A4 | COMPOUNDS AND METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1983-04-25 | — | — | EP | disclosed |
| EP-0065963-A1 | COMPOUNDS AND METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1982-12-08 | — | — | EP | disclosed |
| WO-1982001870-A1 | COMPOUNDS AND METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS | AMERICAN HOSPITAL SUPPLY CORP (US) | 1982-06-10 | — | — | WO | disclosed |
| EP-0053434-A1 | Compounds and method for treatment or prophylaxis of cardiac disorders | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1982-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184322-A1 | NOVEL DIPEPTIDYL-PEPTIDASE-IV INHIBITORS | DPP4, DPP7, DPP3 | L3MBTL1 2131/4885KDM4E 1265/4885TSHR 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.